18.1 C
Delhi
Tuesday, January 14, 2025

Tag: LIVTENCITY

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

Business Wire India  LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant...

- A word from our sponsors -

spot_img

Follow us

HomeTagsLIVTENCITY